Exelixis exelixis.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has ...Show all

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug di...Show all

Company (IPO / Went public)

Phone: (650) 837-7000

Fax:

1851 Harbor Bay Parkway

Alameda, 94502
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Exelixis $42.3M Apr 25, 2005
See all 58 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Exelixis Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Arcion Therapeutics

Baltimore, Maryland, United States
Alive / ActiveArcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to tar...Show allLogin to see details

Threshold Pharmaceuticals

Redwood City, California, United States
MergedThreshold Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor and certain other diseased cells, Threshold's pipeline of drug candidates holds promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical foc...Show allLogin to see details
See all 58 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Process for preparing quinoline derivatives Apr 20, 2016 May 15, 2018 Patent
Method of treating cancer May 02, 2013 Jan 09, 2018 Patent
Lxr modulators Mar 14, 2014 Dec 05, 2017 Patent
Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer Jul 25, 2014 Nov 07, 2017 Patent
Process for making compounds for use in the treatment of cancer Apr 13, 2015 Sep 26, 2017 Patent
See all 99 patents